Hence the effect we see on RANKL and the RANKL/OPG ratio in women who get clinical manifest breast cancer close to serum collection may be triggered by an effect of epithelial/tumor cells altering RANKL/OPG in the bone marrow. This evidence concerns the gene TNFRSF11B and breast carcinoma.